See more : AF Acquisition Corp. (AFAQU) Income Statement Analysis – Financial Results
Complete financial analysis of Satellos Bioscience Inc. (MSCLF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Satellos Bioscience Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fortune Brands Home & Security, Inc. (FBHS) Income Statement Analysis – Financial Results
- Asian Capital Resources (Holdings) Limited (8025.HK) Income Statement Analysis – Financial Results
- The Monogatari Corporation (3097.T) Income Statement Analysis – Financial Results
- Country Club Hospitality & Holidays Limited (CCHHL.NS) Income Statement Analysis – Financial Results
- LiveCare, Inc. (LVCE) Income Statement Analysis – Financial Results
Satellos Bioscience Inc. (MSCLF)
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases. Its lead program focuses on the development of oral therapeutic drug to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 25.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.82M | 336.95K | 119.92K | 48.16K | 3.06K | 1.54K | 23.49K | 27.42K | 22.01K |
| Gross Profit | -8.82M | -336.95K | -119.92K | -48.16K | 21.94K | -1.54K | -23.49K | -27.42K | -22.01K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 87.75% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 8.82M | 2.59M | 1.88M | 892.78K | 917.48K | 1.42M | 787.01K | 564.64K | 627.31K |
| General & Administrative | 6.65M | 5.44M | 2.60M | 904.97K | 835.81K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 35.04K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.65M | 5.44M | 2.60M | 904.97K | 1.29M | 779.74K | 662.85K | 639.07K | 1.56M |
| Other Expenses | -8.82M | -48.67K | -84.44K | -75.01K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.65M | 8.38M | 4.54M | 1.43M | 2.20M | 2.20M | 1.45M | 1.20M | 2.19M |
| Cost & Expenses | 15.46M | 8.38M | 4.66M | 1.48M | 2.21M | 2.20M | 1.47M | 1.23M | 2.21M |
| Interest Income | 1.16K | 20.63K | 7.99K | 4.97K | 0.00 | 417.00 | 6.41K | 16.59K | 40.94K |
| Interest Expense | 0.00 | 0.00 | 985.33K | 23.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.00K | 336.95K | 165.69K | 422.00 | 3.06K | 1.54K | 23.49K | 27.42K | 22.01K |
| EBITDA | -15.46M | -8.09M | -4.60M | -1.54M | -2.00M | -2.20M | -1.45M | -1.20M | -2.19M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -8,810.44% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -15.46M | -8.41M | -4.74M | -1.55M | -2.21M | -2.20M | -1.47M | -1.23M | -2.21M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -8,822.68% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -426.00K | -2.89M | -10.77M | -33.28K | 2.64K | 499.12K | 236.04K | -258.80K | 416.87K |
| Income Before Tax | -15.89M | -11.32M | -15.51M | -1.58M | -2.20M | -1.70M | -1.24M | -1.49M | -1.79M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -8,812.11% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 5.62K | 900.90K | -51.96K | -264.79K | -415.00 | -6.41K | -16.59K | -40.94K |
| Net Income | -15.89M | -11.32M | -15.51M | -1.58M | -1.94M | -1.70M | -1.24M | -1.49M | -1.79M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -7,752.94% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.18 | -0.32 | -0.64 | -1.78 | -0.32 | -0.40 | -0.29 | -0.35 | -0.43 |
| EPS Diluted | -0.18 | -0.32 | -0.64 | -1.78 | -0.32 | -0.40 | -0.29 | -0.35 | -0.43 |
| Weighted Avg Shares Out | 86.40M | 35.68M | 24.08M | 887.79K | 6.12M | 4.22M | 4.22M | 4.22M | 4.22M |
| Weighted Avg Shares Out (Dil) | 86.40M | 35.68M | 24.08M | 887.79K | 6.12M | 4.22M | 4.22M | 4.22M | 4.22M |
Satellos to Participate in Oppenheimer Movers in Rare Disease Summit
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) (“Satellos”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Frank Gleeson, Co-founder and CEO will participate in Oppenheimer's Movers in...
Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced participation in a live investor webinar (the "Webinar") focused...
Satellos to Participate in November 2024 Investor Conferences
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that members of the management team of...
Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that the first participant has been dosed...
Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced submission on July 10, 2024, of a...
Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the formation of a Clinical Advisory Board...
Satellos Bioscience Inc. Opens the Market
TORONTO , May 15, 2024 /PRNewswire/ - Frank Gleeson Co-Founder and Chief Executive Officer, Satellos Bioscience Inc. (TSX: MSCL) ("Satellos" or the "Company"), and his team joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange (TSX), to open...
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of its Annual and Special...
Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today its financial results and operational highlights for...
Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present at and participate...
Source: https://incomestatements.info
Category: Stock Reports